PRIG
ABBV icon

Payden & Rygel Investment Group’s AbbVie ABBV Stock Holding History

Payden & Rygel Investment Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$859K Hold
5,010
– – 0.07% 86
2024
Q1 		$912K Buy
+5,010
New +$863K 0.04% 96
2023
Q3 		$747K Buy
+5,010
New +$735K 0.05% 104

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Payden & Rygel Investment Group's ABBV Position: Q2 2024 in Review

Payden & Rygel Investment Group held its AbbVie (ABBV) position steady in Q2 2024 at 5,010 shares worth $859K. The position accounts for 0.07% of the portfolio, ranked #86.

Payden & Rygel Investment Group first reported a position in ABBV in Q3 2023 and has held it in 3 quarters since. The position peaked at $912K in Q1 2024. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

  • Payden & Rygel Investment Group held 5,010 shares of AbbVie worth $859K as of Q2 2024.
  • Payden & Rygel Investment Group left its AbbVie share count unchanged in Q2 2024.
  • AbbVie made up 0.07% of Payden & Rygel Investment Group's portfolio in Q2 2024, its #86 holding.
  • Payden & Rygel Investment Group first reported a position in AbbVie in Q3 2023 and has held it in 3 quarters since.
  • Payden & Rygel Investment Group's AbbVie position peaked at $912K in Q1 2024.
  • 3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Payden & Rygel Investment Group's 13F filing for Q2 2024, filed 12 Aug 2024.